1. CD Gardner et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A to Z Weight Loss Study: a randomized trial. JAMA 2007; 297:969.

2. FM Sacks et al. Comparison of weight-loss diet with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009; 360:859.

3. GD Foster et al. Weight and metabolic outcomes after 2 years on a low-carbohydrate versus low-fat diet: a randomized trial. Ann Intern Med 2010; 153:147.

4. EA Delbridge et al. One-year weight maintenance after significant weight loss in healthy overweight and obese subjects: does diet composition matter? Am J Clin Nutr 2009; 90:1203.

5. TM Larsen et al. Diets with high or low protein content and glycemic index for weight-loss maintenance. N Engl J Med 2010; 363:2102.

6. BH Goodpaster et al. Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA 2010; 304:1795.

7. WC Knowler et al [Diabetes Prevention Program Research Group]. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.

8. RF Hamman et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 2006; 29:2102.

9. G Li et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371:1783.

10. The Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170:1566.

11. H Jick. Heart valve disorders and appetite-suppressant drugs. JAMA 2000; 283:1738.

12. Z Li et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142:532.

13. In Brief: Orlistat OTC for weight loss. Med Lett Drugs Ther 2007; 49:49.

14. D Rucker et al. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335:1194.

15. Orlistat for obesity. Med Lett Drugs Ther 1999; 41:55.

16. Drugs for tobacco dependence. Treat Guidel Med Lett 2008; 6:61.

17. JW Anderson et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002; 10:633.

18. FL Greenway et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595.

19. TA Wadden et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD Trial. Obesity (Silver Spring) 2011; 19:110.

20. KM Gadde et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003; 289:1820.

21. Zonisamide (Zonegran) for epilepsy. Med Lett Drugs Ther 2000; 42:94.

22. J Wilding et al. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004; 28:1399.

23. J Rosenstock et al. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 2007; 30:1480.

24. RR Wu et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized trial. JAMA 2008; 299:185.

25. L Maayan et al. Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology 2010; 35:1520.

26. Metformin/repaglinide (Prandimet) for type 2 diabetes. Med Lett Drugs Ther 2009; 51:41.

27. Exenatide (Byetta) for type 2 diabetes. Med Lett Drugs Ther 2005; 47:45.

28. JB Buse et al. Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27:2628.

29. RA DeFronzo et al. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28:1092.

30. J Rosenstock et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010; 33:1173.

31. In Brief: exenatide (Byetta) for weight loss. Med Lett Drugs Ther 2006; 48:21.

32. Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther 2010; 52:25.

33. A Astrup et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606.

34. Pramlintide (Symlin) for diabetes. Med Lett Drugs Ther 2005; 47:43.

35. L Aronne et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled dose-escalation study. J Clin Endocrinol Metab 2007; 92:2977.

36. SR Smith et al. Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity. Diabetes Care 2008; 31:1816.

37. WP James et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363:905.

38. SR Smith et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Eng J Med 2010; 363:245.

39. GK Lijesen et al. The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria- based meta-analysis. Br J Clin Pharmacol 1995; 40:237.

40. E Ravussin et al. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity (Silver Spring) 2009; 17:1736.

41. H Buchwald et al. Bariatric surgery: a systematic review and metaanalysis. JAMA 2004; 292:1724.

42. TD Adams et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007; 357:753.

43. The Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med 2009; 361:445.

44. GJ Service et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:249.

45. SA Cunneen et al. Studies of Swedish adjustable gastric band and lapband: systematic review and meta-analysis. Surg Obes Relat Dis 2008; 4:174.

46. NJ Birkmeyer et al. Hospital complication rates with bariatric surgery in Michigan. JAMA 2010; 304:435.

47. Clinical Issues Committee of the American Society for Metabolic and Bariatric Surgery. Updated position statement on sleeve gastrectomy as a bariatric procedure. Surg Obes Relat Dis 2010; 6:1. Epub 2009 Nov 17.

48. MA Makary et al. Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery. Arch Surg 2010; 145:726.

49. L Sjöström et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Eng J Med 2007; 357:741.

50. AE Pontiroli et al. Long-term prevention of mortality in morbid obesity through bariatric surgery. a systematic review and meta-analysis of trials performed with gastric banding and gastric bypass. Ann Surg 2011; 253:484.